[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Belief BioMed (Beijing) Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100597451","phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-efficacy-of-bbm-d101-in-the-treatment-of-duchenne-muscular-dystrophy-100597451",false,"NCT07058662","A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.","A Phase 1\u002F2, Open-label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.","Inclusion Criteria:\n\n1. The Participants and\u002For his legal guardian must fully understand the purpose, nature, methods, and potential risks of the study, and sign a written informed consent form.\n2. Ambulatory male subjects aged 4 years and above but under 9 years (4 years ≤ age \\\u003C 9 years).\n3. Any mutation in the DMD gene confirmed by genetic testing\n4. Serum creatine kinase (CK) during the screening period meets the study requirements.\n5. Receiving stable, standard-dose glucocorticoids before screening.\n6. The subject's AAV capsid antibodies meet the clinical trial requirements.\n7. Able to cooperate with motor function assessment, MRI, and muscle biopsy as required by the study.\n8. Laboratory test results during the screening period and at baseline meet the standards.\n9. The subject and\u002For his legal guardian must fully understand the study procedures, be willing to actively cooperate, commit to high compliance with the protocol, and ensure that the subject attends all scheduled visits.\n\nExclusion Criteria:\n\n1. Positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 1000 U\u002FmL, hepatitis C virus ribonucleic acid (HCV-RNA) positive, human immunodeficiency virus (HIV) positive, or positive for Treponema pallidum antibodies.\n2. Currently receiving antiviral therapy for hepatitis B, hepatitis C, HIV, etc.\n3. The investigator deems the subject has severe behavioral or cognitive disorders that may hinder participation in this study.\n4. Poorly controlled asthma, or Duchenne Muscular Dystrophy (DMD) leading to significant decline in lung function, or recurrent infectious pneumonia that the investigator considers may affect respiratory function.\n5. Left ventricular ejection fraction (LVEF) \\\u003C 50% or New York Heart Association (NYHA) cardiac function class ≥ III.\n6. Severe or persistent arrhythmias (such as atrial fibrillation, frequent ventricular premature beats, ventricular bigeminy, ventricular trigeminy, severe bundle branch block, etc.), and congenital heart disease that is evaluated by the investigator as unsuitable for participation in this study.\n7. Any changes in preventive\u002Fcardiomyopathy treatment (initiation of treatment, drug changes, dosing regimen changes, treatment interruption, termination, or restart) within 1 month before the infusion of the study drug.\n8. History of liver diseases such as portal hypertension, splenomegaly, hepatic encephalopathy, liver fibrosis ≥ stage 3, or hepatic nodules\u002Fcysts found by ultrasound during screening, or elevated alpha-fetoprotein with clinical significance as determined by the investigator.\n9. Severe infection (such as pneumonia, pyelonephritis, or meningitis) within 4 weeks before the treatment visit (enrollment may be postponed).\n10. History of gene therapy or cell therapy (such as stem cell transplantation).\n11. History of or current presence of autoimmune diseases, severe renal, gastrointestinal, neurological, or coagulation disorders, malignant tumors, or other diseases.\n12. Other diseases that the investigator deems unsuitable for participation in this study.","MALE","4 Years","9 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.",[28],"DMD",[28,30,31],"gene therapy","Adeno-Associated Virus","RECRUITING","2025-11-28",{"date":35,"type":36},"2025-12-04","ACTUAL",{"date":38,"type":36},"2025-07-31",{"date":40,"type":21},"2031-06-30",{"name":42,"class":43},"Belief BioMed (Beijing) Co., Ltd","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100608207","phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-efficacy-of-bbm-a101-in-the-treatment-of-knee-osteoarthritis-100608207","NCT07198555","A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.","A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis .","Inclusion Criteria:\n\n1. Participants with moderate knee osteoarthritis .\n2. The knee joint was evaluated as having Kellgren-Lawrence grade 2 or 3.\n3. The Body Mass Index (BMI) ranges from 18.0 to 35.0 kg\u002Fm2 (including the boundary values).\n4. Lower titers of antibodies binding to the BBM-A101 capsid in the blood.\n5. Participants who had received adequate treatment with conventional medications previously, experienced recurrence or aggravation of target knee arthritis after discontinuation of medication, and still had moderate pain; during the screening period, the WOMAC pain score of the target knee was ≥ 8 .\n6. From the time of screening to 52 weeks after dosing , the participants had no intention of having children and voluntarily took effective contraceptive measures, and there were no plans for sperm donation or ova donation.\n7. Voluntarily sign the informed consent form and be able to complete the research as required by the clinical trial protocol.\n\n   \\-\n\nExclusion Criteria:\n\n1. There is a possibility of secondary knee osteoarthritis, or the knee joint symptoms may not be caused by knee osteoarthritis, or there may be other medical histories of diseases that other researchers believe could potentially lead to knee osteoarthritic inflammation.\n2. History of lumbar dischernaiation, accompanied by lower limb nerve symptoms that may affect the assessment of the study.\n3. Participants who are unable or unwilling to undergo MRI examination, or who have contraindications to MRI.\n4. Participants who are unable or unwilling to undergo joint fluid extraction.\n5. During the screening period and before dosing, there were clinically significant abnormal values in the laboratory tests, and the researchers believed that these might pose risks to the participants in the clinical trial.\n6. Those with positive results for hepatitis B virus surface antigen or hepatitis B virus deoxyribonucleic acid or hepatitis C virus ribonucleic acid test or human immunodeficiency virus antibody or Treponema pallidum antibody.\n7. Currently undergoing treatment for hepatitis B and hepatitis C.\n8. Participants who had persistent chronic or active infections within the previous 4 weeks were selected.\n9. Participants who had coagulation disorders (such as hemophilia) or existing medical conditions that require anticoagulation therapy and make knee joint injection impossible.\n10. Having or having had cancer or malignant tumors\n11. Having received genetic therapy or stem cell therapy before screening or having plans for genetic therapy or stem cell therapy during the study period.\n12. Any history of vaccination within 30 days prior to dosing or any vaccination schedule within 30 days after dosing.\n13. Screening will be conducted on female participants who are pregnant or breastfeeding or whose HCG test result is positive; or who have plans to get pregnant within the next 52 w.\n14. History of alcohol addiction or drug dependence, or inability to limit alcohol consumption during the research process.\n15. Participants had any mental disorders that might affect the assessment of the study.\n16. Having other conditions that the investigator consider unsuitable for participation in the study.\n\n    \\-","ALL","40 Years","75 Years",{"count":56,"type":21},81,[24],"The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-A101 to treat participants with knee osteoarthritis.",[60],"Knee Osteoarthritis",[62,30,31],"knee osteoarthritis","2025-11-16",{"date":65,"type":36},"2025-11-18",{"date":67,"type":36},"2025-10-09",{"date":69,"type":21},"2031-12-30",{"name":42,"class":43},""]